NEW YORK (GenomeWeb News) — Agilent Technologies said late yesterday that fiscal first-quarter revenues increased 10 percent as R&D spending increased 1.8 percent and profit declined after a divestiture during the same period last year caused the company to report a large gain.
Total receipts for the three months ended Jan. 31 increased to $1.25 billion from $1.17 billion year over year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.